315 related articles for article (PubMed ID: 25318750)
21. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease.
Wada T; Nangaku M; Maruyama S; Imai E; Shoji K; Kato S; Endo T; Muso E; Kamata K; Yokoyama H; Fujimoto K; Obata Y; Nishino T; Kato H; Uchida S; Sasatomi Y; Saito T; Matsuo S
Kidney Int; 2014 Mar; 85(3):641-8. PubMed ID: 24429394
[TBL] [Abstract][Full Text] [Related]
22. Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.
Musetti C; Quaglia M; Cena T; Chiocchetti A; Monti S; Clemente N; Magnani C; Dianzani U; Stratta P
J Nephrol; 2015 Jun; 28(3):299-305. PubMed ID: 25185729
[TBL] [Abstract][Full Text] [Related]
23. Circulating suPAR in two cohorts of primary FSGS.
Wei C; Trachtman H; Li J; Dong C; Friedman AL; Gassman JJ; McMahan JL; Radeva M; Heil KM; Trautmann A; Anarat A; Emre S; Ghiggeri GM; Ozaltin F; Haffner D; Gipson DS; Kaskel F; Fischer DC; Schaefer F; Reiser J;
J Am Soc Nephrol; 2012 Dec; 23(12):2051-9. PubMed ID: 23138488
[TBL] [Abstract][Full Text] [Related]
24. Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?
Schlöndorff D
Kidney Int; 2014 Mar; 85(3):499-501. PubMed ID: 24583981
[TBL] [Abstract][Full Text] [Related]
25. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
[TBL] [Abstract][Full Text] [Related]
26. The clinical pattern of nephrotic syndrome in children has no effect on the concentration of soluble urokinase receptor (suPAR) in serum and urine.
Ochocińska A; Jarmużek W; Janas R
Pol Merkur Lekarski; 2018 Apr; 44(262):183-187. PubMed ID: 29775445
[TBL] [Abstract][Full Text] [Related]
27. Urinary soluble HLA class I antigen in patients with minimal change disease: a predictor of steroid response.
Park CW; Song HC; Shin YS; Ahn SJ; Kim YS; Kim SY; Choi EJ; Chang YS; Bang BK
Nephron; 1998; 79(1):44-9. PubMed ID: 9609461
[TBL] [Abstract][Full Text] [Related]
28. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
Wu CZ; Chang LC; Lin YF; Hung YJ; Pei D; Chu NF; Chen JS
Clin Biochem; 2015 Dec; 48(18):1324-9. PubMed ID: 26162494
[TBL] [Abstract][Full Text] [Related]
29. The hype cycle for soluble urokinase receptor in FSGS: passing the trough of disillusionment?
Meijers B; Sprangers B
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1835-6. PubMed ID: 25318753
[No Abstract] [Full Text] [Related]
30. Rationale and design of the Japanese Biomarkers in Nephrotic Syndrome (J-MARINE) study.
Kurasawa S; Kato S; Ozeki T; Akiyama S; Ishimoto T; Mizuno M; Tsuboi N; Kato N; Kosugi T; Maruyama S;
Clin Exp Nephrol; 2024 May; 28(5):431-439. PubMed ID: 38267800
[TBL] [Abstract][Full Text] [Related]
31. Serum-soluble urokinase receptor concentration in primary FSGS.
Maas RJH; Wetzels JFM; Deegens JKJ
Kidney Int; 2012 May; 81(10):1043-1044. PubMed ID: 22543906
[No Abstract] [Full Text] [Related]
32. Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome.
Gellermann J; Schaefer F; Querfeld U
Pediatr Nephrol; 2014 Dec; 29(12):2411-4. PubMed ID: 25129204
[TBL] [Abstract][Full Text] [Related]
33. Serum suPAR in patients with FSGS: trash or treasure?
Maas RJ; Deegens JK; Wetzels JF
Pediatr Nephrol; 2013 Jul; 28(7):1041-8. PubMed ID: 23515666
[TBL] [Abstract][Full Text] [Related]
34. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Chen JS; Chang LC; Wu CZ; Tseng TL; Lin JA; Lin YF; Cheng CW
J Biomed Sci; 2016 Feb; 23():24. PubMed ID: 26846181
[TBL] [Abstract][Full Text] [Related]
35. Patients With Combined Membranous Nephropathy and Focal Segmental Glomerulosclerosis Have Comparable Clinical and Autoantibody Profiles With Primary Membranous Nephropathy: A Retrospective Observational Study.
Gu QH; Cui Z; Huang J; Zhang YM; Qu Z; Wang F; Wang X; Wang SX; Liu G; Zhao MH
Medicine (Baltimore); 2016 May; 95(21):e3786. PubMed ID: 27227951
[TBL] [Abstract][Full Text] [Related]
36. Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence.
Mujtaba MA; Sharfuddin AA; Book BL; Goggins WC; Khalil AA; Mishler DP; Fridell JA; Yaqub MS; Taber TE
Clin Transplant; 2015 Jul; 29(7):606-11. PubMed ID: 25973696
[TBL] [Abstract][Full Text] [Related]
37. Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis.
An JN; Hyeon JS; Jung Y; Choi YW; Kim JH; Yang SH; Oh S; Kwon S; Lee SH; Cho JH; Park SH; Ha H; Kim DK; Lee JP; Hwang GS
Sci Rep; 2019 Oct; 9(1):14707. PubMed ID: 31605028
[TBL] [Abstract][Full Text] [Related]
38. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
Alachkar N; Li J; Matar D; Vujjini V; Alasfar S; Tracy M; Reiser J; Wei C
BMC Nephrol; 2018 Dec; 19(1):361. PubMed ID: 30558559
[TBL] [Abstract][Full Text] [Related]
39. MeSsAGe risk score: tool for renal biopsy decision in steroid-dependent nephrotic syndrome.
Chan CY; Resontoc LP; Qader MA; Chan YH; Liu ID; Lau PY; Than M; Yeo WS; Loh AH; Tan PH; Wei C; Reiser J; Biswas SK; Ng KH; Yap HK
Pediatr Res; 2019 Mar; 85(4):477-483. PubMed ID: 30659270
[TBL] [Abstract][Full Text] [Related]
40. Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis.
Beaudreuil S; Zhang X; Kriaa F; Dantal J; Francois H; Vazquez A; Charpentier B; Lorenzo HK; Durrbach A
Nephrol Dial Transplant; 2014 Feb; 29(2):458-63. PubMed ID: 24235085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
